Effect of squalane on mebendazole-loaded Compritol® nanoparticles

The objective of this study is to develop nanostructured lipid formulations of Compritol for the delivery of mebendazole. The formulations were prepared with Compritol 888 ATO, squalane, and Pluronic F68. Nine batches with different amounts of modifier, squalane, and drug were prepared. The formulat...

Full description

Saved in:
Bibliographic Details
Published inJournal of biomaterials science. Polymer ed. Vol. 26; no. 13; pp. 868 - 880
Main Authors Graves, Richard A., Ledet, Grace A., Nation, Cedric A., Pramar, Yashoda V., Bostanian, Levon A., Mandal, Tarun K.
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 02.09.2015
Subjects
Calorimetry, Differential Scanning
Compritol
Drug Carriers - chemistry
Drug Liberation
Fatty Acids - chemistry
mebendazole
Mebendazole - administration & dosage
Mebendazole - pharmacokinetics
Microscopy, Electron, Scanning
Nanoparticles - chemistry
nanostructured lipid
NLC
NLF
Particle Size
Poloxamer - chemistry
squalane
Squalene - analogs & derivatives
Squalene - chemistry
Transition Temperature
Tubulin Modulators - administration & dosage
Tubulin Modulators - pharmacokinetics
squalane
NLF
nanostructured lipid
Compritol
mebendazole
NLC
Online AccessGet full text

Cover

More Information
Summary:The objective of this study is to develop nanostructured lipid formulations of Compritol for the delivery of mebendazole. The formulations were prepared with Compritol 888 ATO, squalane, and Pluronic F68. Nine batches with different amounts of modifier, squalane, and drug were prepared. The formulations were characterized by evaluating particle size, morphology, and zeta potential. The thermal properties of the formulations were analyzed by differential scanning calorimetry (DSC). The encapsulation efficiency of each formulation and the drug release rates from each formulation were quantified by UPLC. The particles were spherical and had median particle sizes between 300 and 600 nm (50th percentile). A linear relationship was observed between Compritol/squalane composition and the melting point of the mixture. The DSC scans of the formulations revealed some recrystallization of the drug from the formulations, and the amount of recrystallization correlated with the amount of squalane in the formulation. Approximately, 70% efficiency of encapsulation was observed in the formulations with 30% (w/w) squalane, and these formulations also had faster dissolution rates compared to the other formulations. Overall, the formulations with 30% squalane are the preferred formulation for future testing.
ISSN:0920-5063
1568-5624
DOI:10.1080/09205063.2015.1061351